HUTCHMED (China) Ltd Files January 2025 6-K Report

Ticker: HMDCF · Form: 6-K · Filed: Jan 14, 2025 · CIK: 1648257

Hutchmed (China) LTD 6-K Filing Summary
FieldDetail
CompanyHutchmed (China) LTD (HMDCF)
Form Type6-K
Filed DateJan 14, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, 6-K, foreign-private-issuer

TL;DR

HUTCHMED filed its Jan 2025 6-K, confirming 20-F annual reports. Standard update.

AI Summary

HUTCHMED (China) Limited filed a Form 6-K on January 14, 2025. This report is for the month of January 2025 and indicates that the company files annual reports under Form 20-F. The company's principal executive offices are located at 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

Why It Matters

This filing serves as an update for investors regarding HUTCHMED's reporting status and administrative details, ensuring transparency in their regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a routine administrative report and does not contain new financial or operational information that would typically indicate significant risk.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company may be required to disclose or make public in its home country.

Which annual report form does HUTCHMED (China) Limited file?

HUTCHMED (China) Limited files its annual reports under cover of Form 20-F.

What is the filing date of this Form 6-K?

This Form 6-K was filed on January 14, 2025.

Where are HUTCHMED's principal executive offices located?

HUTCHMED's principal executive offices are located at 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

What is the SIC code for HUTCHMED (China) Ltd?

The Standard Industrial Classification (SIC) code for HUTCHMED (China) Ltd is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 177 words · 1 min read · ~1 pages · Grade level 14.1 · Accepted 2025-01-14 06:05:43

Filing Documents

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant's name into English) 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F HUTCHMED (CHINA) LIMITED Form 6-K EXHIBIT INDEX Exhibit No. Description Exhibit 99.1 Press release relating to HUTCHMED announces NMPA full approval for ORPATHYS (savolitinib) in China for patients with locally advanced or metastatic MET exon 14 NSCLC 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. HUTCHMED (CHINA) LIMITED By: /s/ Johnny Cheng Name: Johnny Cheng Title: Chief Financial Officer Date: January 14, 2025 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing